B. Monk, T. Van Gorp, D. Lorusso, R. Eilish O’Cearbhaill, A. Westermann, Sri Banerjee, D. Collins, J. Klat, K. Madsen, J. Baurain, A. Jackson, I. Boere, S. Pignata, E. Gort, J. Moroney, I. Soumaoro, CM Andreassen, L. Nicacio, C. Gennigens, I. Vergote
{"title":"替妥单抗韦多汀(TV) +贝伐单抗或派姆单抗或卡铂治疗复发/转移性宫颈癌(R/MCC): 1B/2期engot-CX8/GOG-3024/innovaTV 205研究剂量递增结果","authors":"B. Monk, T. Van Gorp, D. Lorusso, R. Eilish O’Cearbhaill, A. Westermann, Sri Banerjee, D. Collins, J. Klat, K. Madsen, J. Baurain, A. Jackson, I. Boere, S. Pignata, E. Gort, J. Moroney, I. Soumaoro, CM Andreassen, L. Nicacio, C. Gennigens, I. Vergote","doi":"10.1136/ijgc-2021-igcs.13","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19692,"journal":{"name":"Oral abstracts","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"O013/#573 Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (R/MCC): phase 1B/2 engot-CX8/GOG-3024/innovaTV 205 study dose-escalation results\",\"authors\":\"B. Monk, T. Van Gorp, D. Lorusso, R. Eilish O’Cearbhaill, A. Westermann, Sri Banerjee, D. Collins, J. Klat, K. Madsen, J. Baurain, A. Jackson, I. Boere, S. Pignata, E. Gort, J. Moroney, I. Soumaoro, CM Andreassen, L. Nicacio, C. Gennigens, I. Vergote\",\"doi\":\"10.1136/ijgc-2021-igcs.13\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19692,\"journal\":{\"name\":\"Oral abstracts\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2021-igcs.13\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2021-igcs.13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
O013/#573 Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (R/MCC): phase 1B/2 engot-CX8/GOG-3024/innovaTV 205 study dose-escalation results